Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Wesley McGehee

Physician Assistant Fayetteville, AR Physician Assistant

NPI 1063878387 CMS profile 10597522

3352 N Futrall Dr, Fayetteville, AR 72703

Open in the dashboard

General payments

$5,661

92 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wesley McGehee of Fayetteville, AR is reported in the CMS Open Payments database as having received $5,661 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,095 44
2024 General $238 9
2023 General $1,028 35
2022 General $300 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wesley McGehee
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Wesley McGehee were reported at $4,095. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Wesley McGehee Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $300 $155 $48–$522 $149
2023 $1,028 $167 $52–$557 $160
2024 $238 $178 $55–$600 $164
2025 $4,095 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $1,874 4 payments
  2. TissueTech, Inc. $1,372 7 payments
  3. Abbott Laboratories $921 28 payments
  4. Saluda Medical Americas, Inc. $918 35 payments
  5. Medtronic, Inc. $366 13 payments
  6. Nevro Corp. $135 1 payment
  7. SPR Therapeutics, Inc $23 1 payment
  8. Kowa Pharmaceuticals America, Inc. $18 1 payment
  9. Averitas Pharma Inc. $18 1 payment
  10. Bioventus LLC $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,882 85 payments
  2. Travel and Lodging $2,779 7 payments
Products named General payments · program years 2022–2025
  1. General - Therapies $1,874 4 payments
  2. Evoke $918 35 payments
  3. PROCLAIM Neuromodulation $413 11 payments
  4. PROCLAIM Neuromodulation $379 10 payments
  5. INTELLIS ADAPTIVESTIM $268 10 payments
  6. Senza $135 1 payment
  7. PROCLAIM Neuromodulation $61 3 payments
  8. INCEPTIV $60 1 payment
  9. VANTA ADAPTIVESTIM $39 2 payments
  10. PROCLAIM Neuromodulation $31 2 payments
  11. Other $111 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,302

Median for Physician Assistant: 241

Drug cost

$9,783

Median for Physician Assistant: $4,110

Branded share of claims

7.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Baclofen Generic 238 $2,419
Gabapentin Generic 336 $2,025
Tramadol Hcl Generic 261 $1,101
Naloxone Hcl Generic 18 $1,099
Pregabalin Generic 65 $1,001
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 95 $610
Celecoxib Generic 11 $454
Meloxicam Generic 161 $362
Diclofenac Sodium Generic 29 $300
Cyclobenzaprine Hcl Generic 31 $160

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$80,328

Of which drugs: $1,742

Medicare patients

607

Average age 75

Services billed

8,168

384 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Depression 26%
Diabetes 25%
Chronic kidney disease 25%
Atrial fibrillation 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 119 6,517 $655
Injection, methylprednisolone acetate, 40 mg J1030 Office 44 56 $171
Injection, ketorolac tromethamine, per 15 mg J1885 Office 24 48 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record